Clearside Biomedical, Inc.
CLSDQ
$0.95
$0.1215.14%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 201.00K | 492.00K | 2.33M | 306.00K | 1.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 201.00K | 492.00K | 2.33M | 306.00K | 1.04M |
| Cost of Revenue | -- | -- | 248.00K | 149.00K | -- |
| Gross Profit | 201.00K | 492.00K | 2.08M | 157.00K | 1.04M |
| SG&A Expenses | 4.31M | 2.48M | 2.82M | 3.06M | 2.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.24M | 4.06M | 7.54M | 7.46M | 6.97M |
| Operating Income | -7.04M | -3.57M | -5.21M | -7.15M | -5.93M |
| Income Before Tax | -5.97M | -4.50M | -7.51M | -7.31M | -7.69M |
| Income Tax Expenses | -- | -- | 715.00K | -- | -- |
| Earnings from Continuing Operations | -5.97M | -4.50M | -8.22M | -7.31M | -7.69M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.97M | -4.50M | -8.22M | -7.31M | -7.69M |
| EBIT | -7.04M | -3.57M | -5.21M | -7.15M | -5.93M |
| EBITDA | -6.96M | -3.48M | -5.12M | -7.07M | -5.86M |
| EPS Basic | -1.14 | -0.87 | -1.60 | -1.44 | -1.54 |
| Normalized Basic EPS | -0.71 | -0.54 | -0.92 | -0.90 | -0.96 |
| EPS Diluted | -1.14 | -0.87 | -1.60 | -1.44 | -1.54 |
| Normalized Diluted EPS | -0.71 | -0.54 | -0.92 | -0.90 | -0.96 |
| Average Basic Shares Outstanding | 5.23M | 5.19M | 5.13M | 5.06M | 4.98M |
| Average Diluted Shares Outstanding | 5.23M | 5.19M | 5.13M | 5.06M | 4.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |